REGN Stock Analysis: Buy, Sell, or Hold?
REGN - Regeneron Pharmaceuticals Inc
$737.71
-19.02 (-2.51%)
▼
5d:
+0.66%
30d:
-4.29%
90d:
-6.1%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Smart Money Accumulation
REGN is down 3.3% this week, but smart money is accumulating calls. Top strike: $830 2026-04-17 with 103 OI. Call ratio: 85% View Scanner →
Strength: 5.2/10
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: REGN shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: REGN shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1093.32
Based on 5.0% avg growth
INTRINSIC VALUE TODAY
$678.86
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $737.71, which is considered oversold relative to its 30-day fair value range of $745.05 to $780.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.6) compared to its historical average (18.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, REGN is in a uptrend. The price is currently testing key support at $727.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: REGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $873.24 (+18.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, REGN is in a uptrend. The price is currently testing key support at $727.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: REGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $873.24 (+18.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$745.05 -
$780.94
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($873.24)
Fair Price Analysis
30-Day Fair Range
$745.05 -
$780.94
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$48.15
(6.5%)
Support & Resistance Levels
Support Level
$727.88
Resistance Level
$771.23
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.55
Wall Street Target
$873.24
(+18.4%)
Revenue Growth (YoY)
2.5%
Earnings Growth (YoY)
-2.6%
Profit Margin
31.4%
Valuation Discount vs History
-4.9% cheaper
PE vs Historical
15.6 vs 18.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.9%
(market-implied from PE analysis)
1-Year Target
$701.56
(-5%)
2-Year Target
$667.19
(-10%)
3-Year Target
$634.49
(-14%)
3-Yr Target (if PE normalizes)
(PE: 16→18)
$738.62
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 5.9%)
$1264.00
(+71%)
Base:
(SPY PE: 15.5, Growth: 5.9%)
$877.38
(+19%)
Bear:
(PE: 13.2, Growth: 5.9%)
$745.77
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 17.67 | Current EPS (TTM): $41.48
Bull Case
$911.63
(+24%)
Analyst growth 13.1%, PE expands to 19.4
Base Case
$828.76
(+13%)
Market implied 13.1%, PE stable at 17.7
Bear Case
$498.35
(-32%)
Severe decline -20.0%, PE contracts to 15.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.5 to 18.1
Stabilization Target:
$858.77
(+16.4%)
PE Expansion Potential:
+16.4%
Share & Embed Analysis
Last updated: March 30, 2026 7:07 AM ET
Data refreshes hourly during market hours. Next update: 8:07 AM
Data refreshes hourly during market hours. Next update: 8:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
3
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Huda Y Zoghbi
SELL
1638 shares
2026-02-19
Arthur F Ryan
SELL
100 shares
2026-02-09
Jason Pitofsky
SELL
2036 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 60 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
